Cannabics Pharmaceuticals, Inc. (CNBX)


Cannabics Pharmaceuticals, Inc is a biotech company that produces proprietary technologies for medical cannabis therapies.

The company’s flagship product is the Cannabics SR, a sustained release cannabis capsule to provide palliative care to cancer patients. Using a patented formulation, Cannabics SR capsules contain a pure concentrate of cannabinoids from cannabis strains which the company itself selects and breeds. Each capsule is designed to provide 10-12 hours of therapeutic effects, thus allowing for a once-a-day dosage.

Other products in the company’s line are Cannabics IN, a capsule for dry powder inhalers, and Cannabics VP, a condensed pill for standard vaporizers. As of 2013, the company’s products are circulating through five Israel hospitals. It is noted that Israel permits medical marijuana use for patients with cancer and pain-related illnesses.

Cannabics Pharmaceuticals is based in Bethesda, Maryland. According to the company website, it is developing advanced cannabinoid-based therapies through its research and development arm in Israel. It is also collaborating with medical centers in Israel, the US (including states like Colorado and California), and Europe (including countries like Spain, Czech Republic, and the Netherlands) to launch clinical studies on their products.

Cannabics Pharmaceuticals, Inc is a fairly new name in the marijuana industry. It is a subsidiary of Cannabics, Inc, which was founded in 2012 by researchers in molecular biology, pharmacology, and cancer research. The pharmaceuticals company was also formerly known as Thrust Energy Corp until 2011, and as American Mining Corporation just until June 2014.

The company is currently traded in OTC markets as CNBX, with a market cap of USD 32.7 M. Its key executives are Dr. Zohar Koren, Co-founder and CEO; Dr. Eyal Ballan, Co-founder and CTO; and Itamar Borochov, VP of Marketing.

Yahoo! Finance: CNBX News

Latest Financial News for CNBX

Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

TEL AVIV, Israel and BETHESDA, Maryland, April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies. The apoptotic/cytotoxic effects of a multitude of cannabinoid extracts will be evaluated via Cannabics' high throughput screening platform. Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said: "We believe this is a quantum leap for the research on the biology of cancer and cannabinoids.

OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...

SodaStream CEO Daniel Birnbaum to Join Seedo Board

Seedo Corp. is an agro-tech company providing the world's first fully automated and controlled indoor growing machine for pesticide-free agricultural and vertical farming markets. Cannabics owns approximately 20% of Seedo Corp.'s issued and outstanding common stock.

Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.

Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

Companies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions HOD HASHARON, Israel , March 6 , 2019  /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" ...